
Mainboard IPO
Sahajanand Medical Technologies IPO
Prices in INR · Times in IST
GMP updated: 23 Oct 2026, 08:24 AM IST
- Price band
- ₹327 – ₹344
- Application estimate
- ₹14,7921 lot(s) · 43 sh
- GMP · unofficial
- ₹17 (+4.94%)
- Est. listing price
- ₹361Issue price + GMP
- Issue size
- ₹475.48 Cr
- Total subscription
- 14.2×
GMP trend & intraday history
Hover or tap on the chart to inspect a reading. Dates use calendar spacing; large gaps are not connected.
- High in this view
- ₹43 (₹1,849)
- Low in this view
- ₹15 (₹645)
- Reference issue price
- ₹344
- Readings in this view
- 13
- Subject to sauda
- 500 / 7000
Issue at a glance
IPO timetable & schedule
Subscription by investor category
Source updated: 23 Oct 2026, 06:30 PM IST
Overall Demand: 14.2×Mainboard figures are consolidated. NSE and BSE demand is not added together. Rupee demand is calculated from bid shares and the cap price; it is not an exchange-published amount. Application source: boa.
QIB funding cost illustration
Arithmetic for a fully funded institutional bid over 7 days; not a recommendation or a retail return estimate.
- Days
- 7
- Interest Rate
- Not published
- Cost Per Share
- 11936.8
Day-wise subscription history
One snapshot near each bidding day’s close. This is not a continuous intraday series.
Plan your application
Estimate uses the published lot size and upper price band. Confirm your category and the offer terms before applying.
One lot: ₹14,792 · Allocation is not guaranteed. Broker cut-off times may differ.
Source-published application tiers
Before you place an IPO application
- Read the issue. Check the offer document, business risks, price band and your application category.
- Apply through your broker or bank. Use your existing broker’s IPO section or your bank’s ASBA facility. This page does not submit a bid.
- Check the payment step. If using UPI, confirm the mandate in your UPI app and check that the funds are blocked. A saved bid alone is not confirmation.
- Track what happens next. Keep your application number. Use the registrar’s official page for allotment and the published timeline for refunds, demat credit and listing.
GMP return scenario
What could this amount look like?
GMP-based scenario · Not a forecast
Assumes all requested shares are allotted and listing equals issue price + GMP. Actual allotment, listing price, fees and taxes can change the result.
Your IPO progress
Keep your own record of this IPO. Statuses are entered by you, not verified with a broker or registrar. Saved on this browser for your signed-in account; not synced across devices.
IPO reservation & shares offered
Shares offered by category
Category-wise allocation percentages follow SEBI ICDR norms as stated in the offer document.
Promoter holding & ownership
Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust
Promoters hold 40.82% before the issue and will hold 36.2% after it.
Anchor investors & allocations
- Anchor entities
- 10
- Total allocation (₹ crore)
- 140.06
- Mutual fund allottees
- 7
- Official allocation document
- Anchor document: not published
Investor allocations
By fund house
Financials & valuation
Figures in Rs. Crore · Changes compare matching annual period-end dates only.
- Profit After Tax
- 15.09Latest: 30 Jun 2026Prior (31 Mar 2026): 69.08 · YoY unavailable
- EBITDA
- 48.58Latest: 30 Jun 2026Prior (31 Mar 2026): 170.66 · YoY unavailable
- Total Borrowing
- 320.63Latest: 30 Jun 2026Prior (31 Mar 2026): 269.53 · YoY unavailable
Rs. Crore
Key valuation & financial KPIs
- P/E Ratio
- 57.91
- EPS (₹)
- 5.94
- RoE
- 2.07%
- RoCE
- 3.16%
- RoNW
- 2.31%
- PAT Margin
- 4.29%
- EBITDA Margin
- 13.81%
- Debt / Equity
- 0.33
- NAV (₹)
- 64.35
What does the company do?
Sahajanand Medical Technologies Ltd. was founded in 2001 by Dhirajlal Kotadia. It is a medical device company focused on Class III and Class C/D devices, mainly for vascular and structural heart intervention. It was the first company in the world to get CE certification for a drug-eluting stent with a biodegradable polymer, called Infinnium. The products fall in three groups. Vascular intervention covers coronary stents and balloons. Structural heart covers TAVI and occluders. Other products include renal stents, peripheral drug-coated balloons and some trading products. The company has two R&D centres, one in India and one in Thailand, with 102 professionals. It holds 102 granted patents globally and has 71 pending applications. Key brands are Supraflex Cruz, Hydra (TAVI) and Cocoon (occluders), backed by 72 clinical studies and sold in over 76 countries. It sells directly in Germany, Spain, France and the UK, uses a hybrid model in India and distributors in markets such as Italy. As of 31 March 2025 it had 1,458 full-time staff, 24 consultants and 818 contract personnel.
More about the business
Sahajanand Medical Technologies makes Class III heart devices such as drug-eluting stents, TAVI valves and occluders. Total income was Rs 1,218.73 crore in FY2026 and restated profit after tax was Rs 69.08 crore.
Where will the money go?
Strengths & risks
Business strengths
- Total income grew from Rs 908.59 crore in FY2024 to Rs 1,035.96 crore in FY2025 and Rs 1,218.73 crore in FY2026.
- Profit after tax moved from a loss of Rs 7.35 crore in FY2024 to Rs 25.15 crore in FY2025 and Rs 69.08 crore in FY2026.
- EBITDA rose from Rs 110.05 crore in FY2024 to Rs 170.66 crore in FY2026, with an EBITDA margin of 13.81%.
- Net worth rose from Rs 526.30 crore in FY2024 to Rs 616.05 crore in FY2026, and Rs 631.72 crore on 30 June 2026.
- The company holds 102 granted patents and its products are backed by 72 clinical studies.
- Products are sold in over 76 countries, with direct operations in Germany, Spain, France and the UK.
Risks to understand
- The whole issue is an offer for sale of Rs 475.48 crore. The company receives no money from it, so none of the proceeds fund growth or reduce borrowing.
- At the upper band of Rs 344 the issue is priced at 57.91 times post issue EPS of Rs 5.94. One lot is 43 shares, about Rs 14,792 at the upper band.
- RoNW is 2.31% and RoCE is 3.16%, which are low for the size of the business, and FY2024 was a loss year.
- Total borrowing rose from Rs 175.27 crore in FY2024 to Rs 269.53 crore in FY2026 and Rs 320.63 crore on 30 June 2026.
- Promoter holding falls from 40.82% before the issue to 36.2% after it.
- The business depends on regulated Class III devices, so product approvals, clinical results and tenders can affect revenue.
- Sales are spread over many countries, so currency moves and local rules can affect results.
Source-provided company information. Read the RHP for the complete risk factors; these points are not a recommendation.
Listing performance
Actual listing figures appear after listing. Current gain is source-adjusted for corporate actions. CMP is a source snapshot, not a streaming quote.
Official documents, registrar & contacts
Offer documents
MUFG Intime India Private Limited
Phone: 022-49186000
Email: sahajanandmedical.ipo@in.mpms.mufg.com
Allotment date: 21 Oct 2026
- •HSBC Securities & Capital Markets (India) Pvt. Ltd.
- •Nuvama Wealth Management Ltd.
- •Motilal Oswal Investment Advisors
- •Avendus Capital
Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat, 395004
Phone: 022 49564000
Email: investors.grievance@smt.in
Continue your IPO research
Explore more IPO companies
Related by issue type, with active issues first. These are research links, not investment recommendations.